CellFE, Inc., a San Carlos, Calif.-based startup developing a microfluidics based device to deliver gene-editing molecules, raised $3.6m in an initial seed funding.
The round was co-led by Cota Capital and Dynamk Capital, and joined by Embark Ventures. The funding is expected to close with additional investors by the end of January 2020.
The company intends to use the capital to expand operations.
Led by Alla Zamarayeva, CEO, CellFE focuses on the application of microfluidics in the process of delivering gene-editing molecules into human cells. The company has developed technology that uses rapid cell compressions to drive cells to uptake molecules from the surrounding fluid. This technology enables the manufacturing of ex vivo cell and gene therapies in a compact and scalable manner.